US OptionsDetailed Quotes
GSK250502C26500
- 12.58
- 0.000.00%
15min DelayClose May 2 16:00 ET
0.00High0.00Low
12.58Open12.58Pre Close0 Volume1 Open Interest26.50Strike Price0.00Turnover0.00%IV0.03%PremiumMay 2, 2025Expiry Date12.57Intrinsic Value100Multiplier0DDays to Expiry0.01Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma3.16Leverage Ratio--Theta--Rho--Eff Leverage--Vega
GlaxoSmithKline Stock Discussion
Sign in to post a comment
$GlaxoSmithKline (GSK.US)$ is scheduled to report its Q1 2025 results (for the period ending 31 March 2025) tomorrow, Wednesday, 30 April 2025, before the London market opens (around 7:00 AM BST).
Earnings Per Share (EPS):Analysts generally expect Q1 EPS to be slightly lower than the same period last year.For the US-listed ADS (American Depositary Shares), consensus estimates range from approximately $1.04 to $1.0...
Earnings Per Share (EPS):Analysts generally expect Q1 EPS to be slightly lower than the same period last year.For the US-listed ADS (American Depositary Shares), consensus estimates range from approximately $1.04 to $1.0...
+2
6
2
$GlaxoSmithKline (GSK.US)$
Breakthrough: CDC Panel Endorses GSK's Revolutionary 5-in-1 Meningococcal Vaccine PENMENVY
Breakthrough: CDC Panel Endorses GSK's Revolutionary 5-in-1 Meningococcal Vaccine PENMENVY
On Monday (14 April) around 1030 ET, we saw the S&P 500 futures up by 1.4% rise. Nasdaq 100 futures also up by 1.6% while DJIA futures are up by 0.9%.
This show a positive trend in early trading and buying interest was fueled by the reports that President Trump exempted items like smartphones, semiconductors, and other electronics from tariffs.
But S&P 500 only managed to close 0.8% higher than previous week Friday after it went negative brie...
This show a positive trend in early trading and buying interest was fueled by the reports that President Trump exempted items like smartphones, semiconductors, and other electronics from tariffs.
But S&P 500 only managed to close 0.8% higher than previous week Friday after it went negative brie...
+3
24
$GlaxoSmithKline (GSK.US)$
GSK Doubles Down: $4M Investment Tackles Critical Adult Vaccination Gap
GSK Doubles Down: $4M Investment Tackles Critical Adult Vaccination Gap
1
Morning Movers
Gapping Up
$Diageo (DEO.US)$ shares rose 4.6% in pre-market trading, as U.S. tariffs avoided the worst-case scenario for spirits. Goodbody noted no new duties on Canadian and Mexican imports, while Jefferies highlighted the avoidance of a potential 200% tariff on EU alcohol, benefiting European distillers.
Pharmaceutical shares are up in pre-market trading as drug imports could be exempt from the new 'reciprocal ta...
Gapping Up
$Diageo (DEO.US)$ shares rose 4.6% in pre-market trading, as U.S. tariffs avoided the worst-case scenario for spirits. Goodbody noted no new duties on Canadian and Mexican imports, while Jefferies highlighted the avoidance of a potential 200% tariff on EU alcohol, benefiting European distillers.
Pharmaceutical shares are up in pre-market trading as drug imports could be exempt from the new 'reciprocal ta...
23
6
8
$GlaxoSmithKline (GSK.US)$
Breakthrough: New UTI Antibiotic Blujepa Shows Superior Results in Clinical Trials
Breakthrough: New UTI Antibiotic Blujepa Shows Superior Results in Clinical Trials
1
GSK: A Powerhouse of Innovation Poised for Explosive Growth
GlaxoSmithKline (GSK) isn't just a pharmaceutical giant; it's a dynamic, science-led global healthcare company at the forefront of tackling some of the world's most pressing health challenges. With a diverse portfolio, a robust pipeline, and a strategic focus on innovation, GSK presents a compelling investment opportunity for those seeking long-term growth and societal impact.
A Broad Portfolio, Serving Diverse Needs:
GSK's product l...
GlaxoSmithKline (GSK) isn't just a pharmaceutical giant; it's a dynamic, science-led global healthcare company at the forefront of tackling some of the world's most pressing health challenges. With a diverse portfolio, a robust pipeline, and a strategic focus on innovation, GSK presents a compelling investment opportunity for those seeking long-term growth and societal impact.
A Broad Portfolio, Serving Diverse Needs:
GSK's product l...
// Current Events
// Saturday events
var myEvent = GSK
myEvent = Saturday
var myValue = Bullish
if (myValue != 5)
{
console.log("DailysDailyNews")
} else {
myEvent = Saturday
myMainEvent = BRK.B
// Saturday events
var myEvent = GSK
myEvent = Saturday
var myValue = Bullish
if (myValue != 5)
{
console.log("DailysDailyNews")
} else {
myEvent = Saturday
myMainEvent = BRK.B
1
GSK PDUFA event Today, next Month ahead several Major FDA events and trial results. GSK is all Bullish on the charts, and about to be the new leader in the Bio Momentum
https://snsim.moomoo.com/share/server/PvrXe?lang=en-us
https://snsim.moomoo.com/share/server/PvrXe?lang=en-us
No comment yet
frankinglily : GSK's specialty growth sounds promising.![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
Shaaaw : Mixed analyst ratings have me cautious.